Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Thessaloniki – page 4

696 clinical trials in Thessaloniki, Greece across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Thessaloniki at a glance
696
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

696 trials in Thessaloniki

Open in trial search

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Non-small cell lung cancer

Recruiting

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Neoplasm malignant

Recruiting

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Non-small cell lung cancer

Recruiting

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

Non-small cell lung cancer

Recruiting

A study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Small cell lung cancer extensive stage

Recruiting

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Chronic graft versus host disease

Recruiting

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Idiopathic pulmonary fibrosis

Recruiting

Efficacy and Safety of Oral PIPE-791 in Adults with Idiopathic Pulmonary Fibrosis: A Phase 2 Randomized, Double‑Blind, Placebo‑Controlled Study

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years

Plasma cell myeloma refractory

Recruiting

Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma Patients Receiving JNJ-79635322 and Human Normal Immunoglobulin (IV)

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Janssen Cilag International

Gastrointestinal stromal tumour

Recruiting

Phase 3 Study of GSK6042981 versus Imatinib in Adults with Previously Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors (GIST)

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Imatinib Mesilate
  • Sponsor:Glaxosmithkline Research & Development Limited

Other cities in Greece

The busiest research cities in the country

All 50 cities in Greece

Clinical research in Thessaloniki

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, multiple myeloma, and advanced malignancies. Research includes innovative treatments for bladder cancer and gastrointestinal tumors.

  • Advanced cancer therapies
  • Combination treatment approaches
  • Novel therapeutic agents

Investigations emphasize improving survival outcomes and treatment efficacy.

02 Autoimmune Conditions

Clinical trials addressing various autoimmune disorders including cutaneous lupus erythematosus, systemic sclerosis, and Sjögren's Syndrome. Studies evaluate new biologics and targeted therapies.

  • Skin manifestations
  • Systemic complications
  • Immune system modulation

Research focuses on developing more effective treatments with improved safety profiles.

03 Metabolic Disorders

Comprehensive studies on Type 1 Diabetes and obesity, investigating novel therapeutic approaches. Trials examine treatments for weight management and glycemic control.

  • Blood sugar management
  • Weight control interventions
  • Cardiovascular outcomes

Research aims to improve patient outcomes through innovative treatment combinations.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.